Development and validation of a novel mitophagy-related gene prognostic signature for glioblastoma multiforme
By: Wang, Jinghua, Qiu, Xinqi, Huang, Jiayu, Zhuo, Zewei, Chen, Hao, Zeng, Ruijie, Wu, Huihuan, Guo, Kehang, Yang, Qi, Ye, Huiling, Huang, Wei, Luo, Yujun

BioMed Central
2022-06-13; doi: 10.1186/s12885-022-09707-w

Abstract

Background

Glioblastoma multiforme (GBM) is one of the most malignant tumors in brain with high morbidity and mortality. Mitophagy plays a significant role in carcinogenesis, metastasis, and invasion. In our study, we aim to construct a mitophagy-related risk model to predict prognosis in GBM.

Methods

RNA-seq data combined with clinical information were downloaded from TCGA. The 4-gene risk model and nomograph was then constructed and validated in external cohort. Evaluation of immune infiltration, functional enrichment and tumor microenvironment (TME) were then performed.

Result

A mitophagy-related risk model was established and patients in TCGA and CGGA were classified into low-risk and high-risk groups. In both cohorts, patients in low-risk group had improved survival, while high-risk group had poor prognosis. Also, the risk model was identified as an independent factor for predicting overall survival via Cox regression. Furthermore, a prognostic nomogram including mitophagy signatures was established with excellent predictive performance. In addition, the risk model was closely associated with regulation of immune infiltration as well as TME.

Conclusion

In conclusion, our study constructed a mitophagy-related risk model, which can be utilized for the clinical prognostic prediction in GBM.







Copyright 2026 InterMDnet | Privacy Policy | Disclaimer | System Requirements